Medicus Pharma (MDCX) Common Equity (2023 - 2025)

Medicus Pharma has reported Common Equity for 3 years, with the latest figure at -$67554.0 in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 102.16% year-over-year to -$67554.0; the trailing twelve-month figure through Dec 2025 stood at -$67554.0 (down 102.16% YoY), and the FY2025 full-year result was -$67554.0, down 102.16% from the prior year.
• Common Equity for Q4 2025 stood at -$67554.0, up from -$910126.0 in the prior quarter.
• The five-year high for Common Equity was $7.1 million in Q2 2024, with the low at -$910126.0 in Q3 2025.
• Historically, Common Equity has averaged $2.2 million across 3 years, with a median of $2.1 million in 2025.
• The largest YoY upside for Common Equity was 483.52% in 2025 against a maximum downside of 118.98% in 2025.
• Medicus Pharma's Common Equity stood at $1.1 million in 2023, then jumped by 182.04% to $3.1 million in 2024, then sank by 102.16% to -$67554.0 in 2025.
• The last three Common Equity figures came in at -$67554.0 (Q4 2025), -$910126.0 (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.